GlaxoSmithKline Starts Late-Stage Trials for Experimental Antibiotic

October 30, 2019

By Reuters Staff

(Reuters) - GlaxoSmithKline Plc said on Monday it has begun two late-stage studies testing its experimental antibiotic in patients with uncomplicated urinary tract infections or gonorrhea.

The antibiotic, gepotidacin, is the first of a new class of drugs and is expected to treat two common bacterial infections that have been identified as antibiotic-resistant threats by U.S. health regulators.

Health officials across the world have called for the development of newer versions of antibiotics as the growing problem of antibiotic resistance renders some of the most commonly prescribed treatments ineffective.

GSK's antibiotic will be compared to a combination of ceftriaxone and azithromycin in about 600 patients with urogenital gonorrhea, and against nitrofurantoin in nearly 1,200 women with uncomplicated urinary tract infections. (

Gepotidacin belongs to new class of antibiotics called triazaacenaphthylene bacterial topoisomerase inhibitors. The drugs work by selectively interacting with two bacterial enzymes that aid in bacterial replication, making its mechanism of action different from other approved antibiotics, the company said.

GSK expects to announce initial results from the study by the end of 2021.